BR112014023572A2 - método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes - Google Patents

método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes

Info

Publication number
BR112014023572A2
BR112014023572A2 BR112014023572A BR112014023572A BR112014023572A2 BR 112014023572 A2 BR112014023572 A2 BR 112014023572A2 BR 112014023572 A BR112014023572 A BR 112014023572A BR 112014023572 A BR112014023572 A BR 112014023572A BR 112014023572 A2 BR112014023572 A2 BR 112014023572A2
Authority
BR
Brazil
Prior art keywords
agents
agent
combination
joint damage
incipient
Prior art date
Application number
BR112014023572A
Other languages
English (en)
Inventor
Thomas Ranjeny
Original Assignee
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901189A external-priority patent/AU2012901189A0/en
Application filed by Univ Queensland filed Critical Univ Queensland
Publication of BR112014023572A2 publication Critical patent/BR112014023572A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

“método para tratar ou prevenir dano em articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes” são descritos agentes imunomoduladores que são utilizáveis no tratamento ou prevenção de dano nas articulações. mais particularmente, são descritos imunomoduladores para uso no estímulo de uma resposta toleogênica específica de antígeno para um peptídeo de agrecan, incluindo formas citrulinadas dos mesmos para tratar ou prevenir dano nas articulações, incluindo dano nas articulações de indivíduos com ra precoce ou ra incipiente.
BR112014023572A 2012-03-23 2013-03-25 método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes BR112014023572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012901189A AU2012901189A0 (en) 2012-03-23 Immunomodulatory agents and uses therefor
PCT/AU2013/000303 WO2013138871A1 (en) 2012-03-23 2013-03-25 Immunomodulatory agent and uses therefor

Publications (1)

Publication Number Publication Date
BR112014023572A2 true BR112014023572A2 (pt) 2017-09-12

Family

ID=49221713

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014023572A BR112014023572A2 (pt) 2012-03-23 2013-03-25 método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes

Country Status (17)

Country Link
US (1) US20150216955A1 (pt)
EP (1) EP2827890B1 (pt)
JP (2) JP2015512371A (pt)
KR (1) KR20150010716A (pt)
CN (2) CN104519907A (pt)
AU (1) AU2013234815B2 (pt)
BR (1) BR112014023572A2 (pt)
CA (1) CA2868123A1 (pt)
CL (1) CL2014002522A1 (pt)
EA (1) EA201491748A1 (pt)
IL (1) IL234756A0 (pt)
MX (1) MX2014011488A (pt)
MY (1) MY172706A (pt)
NZ (1) NZ631340A (pt)
PH (1) PH12014502063A1 (pt)
SG (2) SG10201706208SA (pt)
WO (1) WO2013138871A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238747B2 (en) 2010-12-13 2019-03-26 Cel-Sci, Corp Method for inducing an immune response against avian, swine, spanish, H1N1, H5N9 influenza viruses and formulations thereof
WO2012162565A2 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
US10179174B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corp. Method for inducing an immune response and formulations thereof
CN109771444A (zh) * 2019-04-03 2019-05-21 哈尔滨北极神生物工程有限公司 蜂胶氨糖人参皂甙复合胶囊及制备方法
US20220218806A1 (en) * 2019-05-11 2022-07-14 CRL-SCI Corporation Peptides and conjugates for treatment of arthritis
EP4100034A1 (en) * 2020-02-06 2022-12-14 Unigen, Inc. Compositions comprising extracts of aplinia and other plants for improving joint health and treating arthritis
CN112675299B (zh) * 2021-01-06 2023-10-20 黑龙江省百洲生物工程有限公司 一种防控鹅星状病毒复合佐剂灭活疫苗的制备方法
WO2024057793A1 (ja) * 2022-09-13 2024-03-21 国立大学法人信州大学 癌転移を抑制するシトルリン化ペプチド
CN117085118A (zh) * 2023-08-22 2023-11-21 北京大学人民医院 一种瓜氨酸化ii型胶原多肽疫苗及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
ATE130197T1 (de) 1988-06-14 1995-12-15 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US6106840A (en) 1988-06-23 2000-08-22 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
FI87028C (fi) 1989-12-22 1992-11-10 Nokia Mobile Phones Ltd Metod foer att reglera effekt hos en spaenningsstyrd effektfoerstaerkare och koppling foer anvaendning i metoden
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5234140A (en) 1992-07-28 1993-08-10 S. C. Johnson & Son, Inc. Re-useable aerosol container
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
IL129547A (en) 1994-10-26 2001-01-11 Novartis Ag Pharmaceutical compositions comprising a macrolide and an acid
CA2251781A1 (en) 1996-03-20 1997-09-25 Charles Nicolette A method for identifying cytotoxic t-cell epitopes
GB9612629D0 (en) 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery
WO1998002441A2 (en) 1996-07-12 1998-01-22 Ariad Pharmaceuticals, Inc. Non immunosuppressive antifungal rapalogs
WO1999031073A1 (fr) 1997-12-15 1999-06-24 Yamanouchi Pharmaceutical Co., Ltd. Nouveaux derives de pyrimidine-5-carboxamide
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
US20030091583A1 (en) * 2000-03-23 2003-05-15 Hubert Nelissen Robert Louis Use of mia in immunotheraphy
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EA011488B1 (ru) 2002-02-01 2009-04-28 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их получение
US20030235610A1 (en) * 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
CA2421321A1 (en) * 2003-03-07 2004-09-07 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecule and involved in rheumatoid arthritis
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
WO2014176604A1 (en) * 2013-04-26 2014-10-30 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
EP3590503A1 (en) * 2006-10-12 2020-01-08 The University of Queensland Compositions and methods for modulating immune responses
US11041013B2 (en) 2008-03-14 2021-06-22 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
JPWO2009116246A1 (ja) 2008-03-17 2011-07-21 パナソニック株式会社 通信方法、通信システム、モバイルノード及びアクセスルータ
US9063148B2 (en) 2008-10-22 2015-06-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicince, Inc. Immunoassays for citrullinated proteins
JP5744859B2 (ja) 2009-06-15 2015-07-08 ライジェル ファーマシューティカルズ， インコーポレイテッド 脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
WO2014141244A1 (en) * 2013-03-12 2014-09-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Synthetic peptides for the treatment of autoimmune diseases
KR20210057832A (ko) * 2013-03-13 2021-05-21 코어 파마슈티칼스 디벨롭먼트 컴퍼니 인크. 염증 치료용 면역-변형된 입자

Also Published As

Publication number Publication date
CA2868123A1 (en) 2013-09-26
WO2013138871A1 (en) 2013-09-26
EP2827890A1 (en) 2015-01-28
PH12014502063A1 (en) 2014-12-10
CN110404062A (zh) 2019-11-05
JP2019070034A (ja) 2019-05-09
EA201491748A1 (ru) 2015-02-27
CL2014002522A1 (es) 2015-06-12
EP2827890A4 (en) 2015-11-25
US20150216955A1 (en) 2015-08-06
NZ631340A (en) 2016-11-25
AU2013234815A1 (en) 2014-10-09
MY172706A (en) 2019-12-11
JP2015512371A (ja) 2015-04-27
MX2014011488A (es) 2015-05-11
IL234756A0 (en) 2014-11-30
AU2013234815B2 (en) 2017-06-22
KR20150010716A (ko) 2015-01-28
SG11201405848UA (en) 2014-10-30
SG10201706208SA (en) 2017-08-30
CN104519907A (zh) 2015-04-15
EP2827890B1 (en) 2019-08-28

Similar Documents

Publication Publication Date Title
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
CO2019009234A2 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas
WO2017059319A3 (en) Combination therapy of bromodomain inhibitors and checkpoint blockade
MX2022004374A (es) Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cancer.
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
BR112017016068A2 (pt) composições para modulação de expressão de c9orf72
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
EA201590451A1 (ru) Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112014031088A2 (pt) métodos para o tratamento de câncer pancreático usando terapias de combinação que compreendem irinotecano lipossomal
CL2018000963A1 (es) Cosmética que tiene bacterias probióticas
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
BR112015023207A2 (pt) uso de c1-inh no tratamento de desordens associadas à deficiência de inibidor de c1 esterase
BR112018016968A2 (pt) derivados de carboxamida úteis como inibidores de rsk
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.

B350 Update of information on the portal [chapter 15.35 patent gazette]